Answer
Daratumumab (Darzalex) infusion monotherapy is indicated for adults with relapsed and refractory multiple myeloma whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and whose disease progressed on their last therapy.
Sources for this answer
- DARZALEX 20 mg/mL concentrate for solution for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.1 Therapeutic Indications · Version 34Document updated
Sources checked